Q1 2026 earnings + mirdametinib PDUFA July 10 preparation update
Key Notes
Q1 2026 earnings expected ~May 6, 2026. Key update ahead of mirdametinib PDUFA July 10, 2026 (NF1-PN). Commercial build updates, manufacturing readiness. Mirdametinib (ReNeu Phase 3) would be first oral MEK inhibitor specifically for NF1-associated plexiform neurofibromas in adults and pediatric patients. Rare Pediatric Disease designation enables PRV eligibility.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.